Shares of Globus Medical, Inc. (NYSE:GMED – Get Free Report) have been given an average rating of “Moderate Buy” by the twelve brokerages that are presently covering the stock, MarketBeat reports.

Globus Medical (NYSE:GMED – Free Report) had its target price increased by Canaccord Genuity Group from $92.00 to $101.00 in ...

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...

Globus Medical is seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

BofA Securities has upgraded Globus Medical (NYSE:GMED) to neutral from underperform, citing the company's strong Q4 revenue ...

BTIG analyst Ryan Zimmerman reiterated a Buy rating on Globus Medical (GMED – Research Report) today and set a price target of $91.00. The ...

BofA analyst Craig Bijou upgraded Globus Medical (GMED) to Neutral from Underperform with a price target of $97, up from $80, ...

Fintel reports that on January 9, 2025, B of A Securities upgraded their outlook for Globus Medical (NYSE:GMED) from ...

Globus Power Generation Ltd., incorporated in the year 1985, is a Small Cap company (having a market cap of Rs 162.97 Crore) operating in Miscellaneous sector. Globus Power Generation Ltd. key ...

Intimation regarding the resignation of the Company Secretary & Compliance Officer of the Company ...

Globus Spirits Ltd., incorporated in the year 1993, is a Small Cap company (having a market cap of Rs 2,307.39 Crore) operating in Beverages - Alcoholic sector. Globus Spirits Ltd. key ...